2006
Anticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter
Segal J, McNamara R, Miller M, Powe N, Goodman S, Robinson K, Bass E. Anticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter. 2006, 2010: cd001938. PMID: 17636690, PMCID: PMC10759270, DOI: 10.1002/14651858.cd001938.pub2.Peer-Reviewed Original ResearchConceptsAggregate odds ratioRisk of hemorrhageAtrial fibrillationStroke preventionMajor hemorrhageOdds ratioDose warfarinMajor bleedsModerate evidenceCochrane Collaboration's CENTRAL databaseNon-postoperative atrial fibrillationNon-rheumatic atrial fibrillationLow molecular weight heparinAdditional major bleedsLow-dose warfarinMore major bleedingMore major bleedsMore major hemorrhageRCTs of patientsPrimary stroke preventionLow-risk patientsRheumatic valvular diseasePrevention of thromboembolismRisk of strokeTrials of drugs
2001
Anticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter
Segal J, McNamara R, Miller M, Powe N, Goodman S, Robinson K, Bass E. Anticoagulants or antiplatelet therapy for non‐rheumatic atrial fibrillation and flutter. Cochrane Database Of Systematic Reviews 2001, cd001938. PMID: 11279741, DOI: 10.1002/14651858.cd001938.Peer-Reviewed Original ResearchConceptsRisk of hemorrhageAtrial fibrillationStroke preventionMajor hemorrhageDose warfarinMajor bleedsOdds ratioModerate evidenceCochrane Collaboration's CENTRAL databaseNon-postoperative atrial fibrillationNon-rheumatic atrial fibrillationLow molecular weight heparinAdditional major bleedsAggregate odds ratioLow-dose warfarinMore major bleedingMore major bleedsMore major hemorrhageRCTs of patientsPrimary stroke preventionLow-risk patientsRheumatic valvular diseasePrevention of thromboembolismRisk of strokeTrials of drugs
2000
Prevention of Thromboembolism in Atrial Fibrillation
Segal J, McNamara R, Miller M, Kim N, Goodman S, Powe N, Robinson K, Bass E, Center F. Prevention of Thromboembolism in Atrial Fibrillation. Journal Of General Internal Medicine 2000, 15: 56-67. PMID: 10632835, PMCID: PMC1495320, DOI: 10.1046/j.1525-1497.2000.04329.x.Peer-Reviewed Original ResearchConceptsAtrial fibrillationMajor bleedsStroke preventionMajor hemorrhageCochrane Collaboration's CENTRAL databaseAdditional major bleedsMore major bleedingMore major bleedsMore major hemorrhagePrimary stroke preventionPrevention of thromboembolismRisk of hemorrhageTrials of drugsCentral databaseMajor bleedingYounger patientsPrimary preventionMean agePatient riskBaseline riskStroke rateLower riskAspirinPatientsModerate evidenceThe evidence regarding the drugs used for ventricular rate control.
Segal J, McNamara R, Miller M, Kim N, Goodman S, Powe N, Robinson K, Yu D, Bass E. The evidence regarding the drugs used for ventricular rate control. The Journal Of Family Practice 2000, 49: 47-59. PMID: 10678340.Peer-Reviewed Original ResearchConceptsHeart rate controlExercise toleranceAtrial fibrillationHeart rateBetter heart rate controlCochrane Collaboration's CENTRAL databaseCalcium channel blocker verapamilAbstracts of trialsTrial of verapamilImproved exercise toleranceVentricular rate controlTrials of drugsEnglish-language articlesEnglish-language abstractsCentral databaseVentricular rateBlocker verapamilInsufficient evidenceSystematic reviewPlaceboFibrillationTrialsDrugsLanguage publicationsPatients